CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment

Conclusions:
The composite biomarker, CAPG and GIPC1 in primary breast tumors, predicted disease outcomes and benefit from zoledronate and may facilitate patient selection for adjuvant bisphosphonate treatment.

Source: JNCI - January 12, 2016 Category: Cancer & Oncology Authors: Westbrook, J. A., Cairns, D. A., Peng, J., Speirs, V., Hanby, A. M., Holen, I., Wood, S. L., Ottewell, P. D., Marshall, H., Banks, R. E., Selby, P. J., Coleman, R. E., Brown, J. E. Tags: Article Source Type: research